Kaplan–Meier analyses showed significantly lower cumulative incidences of MACE (log-rank p < 0.001), major microvascular complications (log-rank p < 0.001), all-cause mortality (log-rank p < 0.001), hospitalization for coronary artery disease (log-rank p = 0.003), stroke (log-rank p < 0.001), heart failure (log-rank p < 0.001), and ESKD (log-rank p < 0.001) among GLP-1 RA users compared with sulfonylurea users (Figure 2, Figures S5 and S6). The gene discussed is GLP1R; the disease is heart failure.